PET in brain tumors

PET Clinics

Volumn 5, Issue 2, 2010, Pages 185-197

  Hustinx, Roland ^a   Fosse, Pacôme ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

18F fluorodeoxyglucose; Brain tumors; FET; Methyl L methionine; Positron emission tomography

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; GLIOMA; HUMAN; MALIGNANT TRANSFORMATION; MENINGIOMA; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 79954602595     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2010.02.004     Document Type: Article

References (101)

1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97.
3. Scarabino T, Popolizio T, Trojsi F, et al. Role of advanced MR imaging modalities in diagnosing cerebral gliomas. Radiol Med 2009;114:448.
4. Gallagher BM, Fowler JS, Gutterson NI, et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-Dglucose. J Nucl Med 1978;19:1154.
5. Nishioka T, Oda Y, Seino Y, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res 1992;52:3972.
6. Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med 1977;296:486.
7. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323.
8. Herholz K, Pietrzyk U, Voges J, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79:853.
9. Stockhammer F, Thomale UW, Plotkin M, et al. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. J Neurosurg 2007;106:633.
10. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009;36(Suppl 3):S46.
11. Wei LH, Su H, Hildebrandt IJ, et al. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 2008;14:3416.
12. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47.
13. Kim CK, Alavi JB, Alavi A, et al. New grading system of cerebral gliomas using positron emission tomography with F-18 fluorodeoxyglucose. J Neurooncol 1991;10:85.
14. Hustinx R, Smith RJ, Benard F, et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26: 1501.
15. Lilja A, Bergstrom K, Hartvig P, et al. Dynamic study of supratentorial gliomas with L-methyl-11Cmethionine and positron emission tomography. AJNR Am J Neuroradiol 1985;6:505.
16. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 1992;19:227.
17. Coenen HH, Kling P, Stocklin G. Cerebral metabolism of L-[2-18F]fluorotyrosine, a new PET tracer of protein synthesis. J Nucl Med 1989;30:1367.
18. Luxen A, Perlmutter M, Bida GT, et al. Remote, semiautomated production of 6-[18F]fluoro-Ldopa for human studies with PET. Int J Rad Appl Instrum A 1990;41:275.
19. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18Falpha- methyltyrosine using a separation and purification system. Nucl Med Commun 1997;18:169.
20. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205.
21. Ishiwata K, Kubota K, Murakami M, et al. A comparative study on protein incorporation of L- [methyl-3H]methionine, L-[1-14C]leucine and L-2- [18F]fluorotyrosine in tumor bearing mice. Nucl Med Biol 1993;20:895.
22. Roelcke U, Radu EW, von Ammon K, et al. Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci 1995; 132:20.
23. Lahoutte T, Caveliers V, Camargo SM, et al. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its trans-stimulation. J Nucl Med 2004;45:1591.
24. Langen KJ, Hamacher K, Weckesser M, et al. O- (2-[18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 2006;33:287.
25. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 2003; 30:501.
26. Toyohara J, Waki A, Takamatsu S, et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281.
27. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805.
28. Hara T. 18F-fluorocholine: a new oncologic PET tracer. J Nucl Med 2001;42:1815.
29. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997;38:842.
30. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525.
31. Decristoforo C, Knopp R, von Guggenberg E, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870.
32. HenzeM, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-DPhe1- Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001;42:1053.
33. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11- methionine. J Nucl Med 1998;39:778.
34. Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl- 11C-methionine. AJNR Am J Neuroradiol 1996;17: 345.
35. Kosaka N, Tsuchida T, Uematsu H, et al. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008;190:W365.
36. Kitajima K, Nakamoto Y, Okizuka H, et al. Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 2008;22:595.
37. Posther KE, McCall LM, Harpole DH Jr, et al. Yield of brain 18F-FDG PET in evaluating patients with potentially operable nonsmall cell lung cancer. J Nucl Med 2006;47:1607.
38. Ogawa T, Shishido F, Kanno I, et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993;186:45.
39. Braun V, Dempf S, Weller R, et al. Cranial neuronavigation with direct integration of 11Cmethionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases. Acta Neurochir (Wien) 2002;144:777.
40. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316.
41. Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163.
42. Yamane T, Sakamoto S, Senda M. Clinical impact of (11C)-methionine PETon expected management of patients with brain neoplasm. Eur J Nucl Med Mol Imaging 2010;37:685-90.
43. Galldiks N, Kracht LW, Berthold F, et al. [11C]-Lmethionine positron emission tomography in the management of children and young adults with brain tumors. J Neurooncol 2010;96:231.
44. Pauleit D, Floeth F, Hamacher K, et al. O-(2- [18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678.
45. Pauleit D, Stoffels G, Bachofner A, et al. Comparison of 18F-FET and 18F-FDG PET in brain tumors. Nucl Med Biol 2009;36:779.
46. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 2006;47:776.
47. Becherer A, Karanikas G, Szabo M, et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561.
48. Chen W, Silverman DH, Delaloye S, et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904.
49. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746.
50. Kameyama M, Shirane R, Itoh J, et al. The accumulation of 11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 1990;104:8.
51. Kato T, Shinoda J, Nakayama N, et al. Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron- emission tomography. AJNR Am J Neuroradiol 2008;29:1176.
52. Ceyssens S, Van Laere K, de Groot T, et al. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432.
53. Moulin-Romsee G, D'Hondt E, de Groot T, et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine? Eur J Nucl Med Mol Imaging 2007;34:2082.
54. Stockhammer F, Plotkin M, Amthauer H, et al. Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neurooncol 2008;88:205.
55. Popperl G, KrethFW, Mehrkens JH, et al. FET PET for the evaluation of untreated gliomas: correlation of FETuptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007;34:1933.
56. Alavi JB, Alavi A, Chawluk J, et al. Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 1988;62:1074.
57. Patronas NJ, Brooks RA, DeLaPaz RL, et al. Glycolytic rate (PET) and contrast enhancement (CT) in human cerebral gliomas. AJNR Am J Neuroradiol 1983;4:533.
58. De Witte O, Levivier M, Violon P, et al. Prognostic value positron emission tomography with [18F]fluoro- 2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470.
59. Kruer MC, Kaplan AM, Etzl MM Jr, et al. The value of positron emission tomography and proliferation index in predicting progression in lowgrade astrocytomas of childhood. J Neurooncol 2009;95:239.
60. Floeth FW, Pauleit D, Sabel M, et al. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007;48:519.
61. Hanson MW, Glantz MJ, Hoffman JM, et al. FDGPET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796.
62. Pirotte B, Goldman S, Bidaut LM, et al. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir (Wien) 1995;134:79.
63. Pirotte B, Goldman S, Massager N, et al. Comparison of 18F-FDG and 11C-methionine for PETguided stereotactic brain biopsy of gliomas. J Nucl Med 2004;45:1293.
64. Pirotte BJ, Lubansu A, Massager N, et al. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 2007;107:392.
65. Maier H, Ofner D, Hittmair A, et al. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg 1992;77:616.
66. Cremerius U, Bares R, Weis J, et al. Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET. J Nucl Med 1997;38:26.
67. Di Chiro G, Hatazawa J, Katz DA, et al. Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study. Radiology 1987;164:521.
68. Lee JW, Kang KW, Park SH, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 2009;36:1574.
69. Giovacchini G, Fallanca F, Landoni C, et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med 2009;34:7.
70. Giglio P, Gilbert MR. Cerebral radiation necrosis. Neurologist 2003;9:180.
71. Plowman PN. Stereotactic radiosurgery. VIII. The classification of postradiation reactions. Br J Neurosurg 1999;13:256.
72. Patronas NJ, Di Chiro G, Brooks RA, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982; 144:885.
73. Chao ST, Suh JH, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001; 96:191.
74. Gomez-Rio M, Rodriguez-Fernandez A, Ramos- Font C, et al. Diagnostic accuracy of 201Thallium- SPECTand 18F-FDG-PET in the clinical assessment of glioma recurrence. Eur J Nucl Med Mol Imaging 2008;35:966.
75. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994;163:1459.
76. Alexiou GA, Tsiouris S, Kyritsis AP, et al. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 2009;95:1.
77. Terakawa Y, Tsuyuguchi N, Iwai Y, et al. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 2008;49:694.
78. Van Laere K, Ceyssens S, Van Calenbergh F, et al. Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005;32:39.
79. Mehrkens JH, Popperl G, Rachinger W, et al. The positive predictive value of O-(2-[18F]fluoroethyl)- L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 2008;88:27.
80. Rachinger W, Goetz C, Popperl G, et al. Positron emission tomography with O-(2-[18F]fluoroethyl)-ltyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005;57:505.
81. Yamamoto Y, Wong TZ, Turkington TG, et al. 3′-Deoxy-3′-[F18] fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol 2006;8:340.
82. Maher EA, McKee A. Neoplasms of the central nervous system. In: Skarin AT, editor. Atlas of diagnostic oncology. London: Elsevier Science Limited; 2003. p. 403-15.
83. Francavilla TL, Miletich RS, Di Chiro G, et al. Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989;24:1.
84. Ullrich RT, Kracht L, Brunn A, et al. Methyl-L-11Cmethionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med 2009;50:1962.
85. Piroth MD, Pinkawa M, Holy R, et al. Integratedboost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. Radiat Oncol 2009;4:57.
86. Douglas JG, Stelzer KJ, Mankoff DA, et al. [F18]- fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2006;64:886.
87. Tralins KS, Douglas JG, Stelzer KJ, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med 2002;43:1667.
88. Grosu AL, Weber WA, Riedel E, et al. L-(methyl- 11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64.
89. Mahasittiwat P, Mizoe JE, Hasegawa A, et al. l-[METHYL-11C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:515.
90. Weber DC, Zilli T, Buchegger F, et al. [18F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008;3:44.
91. Gehler B, Paulsen F, Oksuz MO, et al. [68Ga]-DOTATOC- PET/CT for meningioma IMRT treatment planning. Radiat Oncol 2009;4:56.
92. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006;65:222.
93. Rutten I, Cabay JE, Withofs N, et al. PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report. J Nucl Med 2007;48:720.
94. Grosu AL, Weber WA, Astner ST, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:339.
95. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987.
96. Brock CS, Young H, O'Reilly SM, et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608.
97. Charnley N, West CM, Barnett CM, et al. Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:331.
98. Wyss M, Hofer S, Bruehlmeier M, et al. Early metabolic responses in temozolomide treated lowgrade glioma patients. J Neurooncol 2009;95:87.
99. Backes H, Ullrich R, Neumaier B, et al. Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma. Eur J Nucl Med Mol Imaging 2009;36:1960-7.
100. Chen W, Delaloye S, Silverman DH, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007;25:4714.
101. Herholz K. Amino acid PET and clinical management of glioma patients. Eur J Nucl Med Mol Imaging 2010;37:683-4.